Latest News for: insilicos

Edit

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI ...

Courier Express 11 Jan 2025
This is the second asset Menarini Group has inlicensed ...
Edit

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an

Hastings Tribune 10 Jan 2025
This is the second asset Menarini Group has inlicensed ...
Edit

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology

PR Newswire 10 Jan 2025
("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage ...
Edit

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology (A Menarini Industrie Farmaceutiche Riunite Srl)

Public Technologies 10 Jan 2025
("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a ...
Edit

Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease

PR Newswire 07 Jan 2025
7, 2025 /PRNewswire/ -- Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announces positive results from ...
Edit

UAE-based Insilico Medicine advances world’s first fully AI-generated drug to clinical trials

GDN Online 14 May 2024
Alex Zhavoronkov, Insilico Medicine’s CEO and an expert in longevity medicine ... The UAE Insilico team is working on other advances to Insilico’s Pharma.AI platform, including the integration of large language models and quantum computing.
Edit

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications (A Menarini Industrie Farmaceutiche Riunite Srl)

Public Technologies 05 Jan 2024
... to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico's AI platform, as a potential treatment for hormone sensitive cancers and other oncology indications.
Edit

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for ...

The Valdosta Daily Times 04 Jan 2024
FLORENCE, Italy & NEW YORK--(BUSINESS WIRE)--Jan 4, 2024-- ... .
Edit

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

PR Newswire 04 Jan 2024
... develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico's AI platform, as a potential treatment for hormone sensitive cancers and other oncology indications. .
Edit

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class ...

Business Wire 13 Sep 2023
EXEL) and Insilico Medicine (“Insilico”) today announced that the companies have entered into an ...
Edit

Exelixis to license Insilico AI-designed cancer drug

Market Watch 12 Sep 2023
The deal gives Insilico an upfront payment of $80 million, expected in the third quarter of this year, and eligibility for future development, commercial and sales-based milestone payments.
Edit

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

Pharmiweb 12 Sep 2023
EXEL) and Insilico Medicine (“Insilico”) today announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a ...
Edit

Global Artificial Intelligence in Drug Discovery Market Research Report 2023-2028 Featuring Major Players - Atomwise, BenevolentAI, Exscientia, Insilico Medicine, Recursion Pharmaceuticals

PR Newswire 28 Aug 2023
Major players in the AI in the drug discovery markets include Atomwise Inc., BenevolentAI, Exscientia, Insilico Medicine, Recursion Pharmaceuticals and many others ... Benevolentai Exscientia plc Insilico Medicine Recursion Pharmaceuticals Inc.
Edit

Insilico Medicine’s generative AI tool inClinico demonstrates high accuracy in predicting clinical trial outcomes

Venture Beat 04 Aug 2023
Insilico Medicine, a clinical-stage AI drug discovery company, announced a groundbreaking medical milestone ... “The more data it has, and the more successful outcomes, the better AI becomes at accurate prediction.” What’s next for Insilico?.
Edit

Qiming-Backed AI Drug Discovery Startup Insilico Medicine Files For Hong Kong IPO

Forbes 29 Jun 2023
Insilico Medicine was valued at about $895 million after raising $95 million last July from the likes of leading Chinese healthcare-focused firm Qiming Venture Partners and billionaire Eduardo Saverin’s B Capital, among others ... .

Article Search

tools

Most Viewed

×
×
×
×